<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="156307">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01800292</url>
  </required_header>
  <id_info>
    <org_study_id>13-0006-01</org_study_id>
    <secondary_id>986-12</secondary_id>
    <nct_id>NCT01800292</nct_id>
  </id_info>
  <brief_title>Characterization of Left Ventricular (LV) Strain Patterns in Mildly Elevated Pulmonary Capillary Wedge Pressure (PCWP) and Pulmonary Artery Hypertension (PAH).</brief_title>
  <acronym>LV strain</acronym>
  <official_title>Echo Study - Characterization of LV Strain Patterns in Patients With Mildly Elevated PCWP and Pulmonary Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arizona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Arizona Sarver Heart Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Arizona</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if patients with pulmonary hypertension and mildly
      elevated heart pressure known as PCWP will exhibit different patterns on echocardiography
      and that these patterns will predict treatment response to sildenafil, a drug given for this
      condition.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">February 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>exercise capacity not on/on sildenafil therapy</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subjects will have 6 minute walk testing prior to sildenafil therapy and 3 months post-initiation of sildenafil therapy.  Improvement in submaximal exercise capacity on sildenafil therapy is defined as ≥ 30 M increase in 6 minute walk testing.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Echo parameters:left ventricular septal and lateral wall longitudinal strain and strain rate, RV strain and strain rate, and LV lateral wall/septal strain and strain rate</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Echo parameters will be collected pre-therapy vs 3 months on sildenafil therapy. Changes in ventricular wall motion will be documented with left ventricular (LV) septal and lateral wall longitudinal strain and strain rate, right ventricular strain and strain rate, and LV lateral wall/septal strain and strain rate utilizing speckle tracking techniques values determined by 2D-Echo.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>World Health Organization functional class</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>World Health Organization functional class (I-IV) will be determined at baseline and at 3 months</description>
  </other_outcome>
  <other_outcome>
    <measure>BNP (brain natriuretic peptide)</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood will be collected to get BNP (brain natriuretic peptide)lab result at baseline and at 3 months</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hypertension, Pulmonary Artery</condition>
  <condition>Ventricular Dysfunction, Left</condition>
  <arm_group>
    <arm_group_label>sildenafil therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will have 2D-Echocardiogram measuring left ventricular strain and strain rate using speckle tracking techniques, have 6  minute walk test, World Health Organization functional class (I-IV)assignment, and BNP lab result at baseline and at 3 months.  Subjects will be started on sildenafil at 20 mg by mouth three times per day at the baseline visit.  Each individual will serve as his/her own control.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sildenafil</intervention_name>
    <description>Subjects will be started on sildenafil at 20 mg PO TID at the baseline visit. Each individual will serve as his/her own control. Subjects will be evaluated at 3 months, with participation completed at that time.</description>
    <arm_group_label>sildenafil therapy</arm_group_label>
    <other_name>Revatio</other_name>
    <other_name>compound UK-92,480</other_name>
    <other_name>Patent 5,250,534</other_name>
    <other_name>sildenafil citrate</other_name>
    <other_name>NDA 22-473</other_name>
    <other_name>C22H30N6O4S.C6H8O7</other_name>
    <other_name>C28H38N6O11S</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with New York Heart Association/World Health
             Organization(NYHA/WHO)functional class II-III

          -  Patients with mean pulmonary artery pressure &gt;25 mmHg, pulmonary capillary wedge
             pressure &gt;15 mmHg ≤18, and pulmonary vascular resistance &gt;3 wood units

          -  Age &gt;18 and &lt;80

          -  Stable on antihypertensives and diuretics&gt;3 months

          -  No evidence of active ischemic heart disease

          -  6 minute walk distance &gt;150 meters and &lt;450 meters

        Exclusion Criteria:

          -  - Left ventricular ejection fraction &lt;50%

          -  Patients with significant restrictive lung disease (FVC&lt;60% predicted) and/or
             significant obstructive lung disease (FEV1 &lt;55% predicted) within 1 year of
             enrollment

          -  Poorly interpretable grey scale echocardiographic images

          -  Contraindications to right heart catheterization

          -  Nitroglycerin therapy

          -  Moderate-severe aortic and mitral valve abnormality

          -  Contraindications to submaximal exercise testing
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aiden Abidov, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arizona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arizona Medical Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 29, 2013</lastchanged_date>
  <firstreceived_date>February 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulmonary Artery Hypertension</keyword>
  <keyword>pulmonary capillary wedge pressure</keyword>
  <keyword>sildenafil</keyword>
  <keyword>echocardiography</keyword>
  <keyword>left ventricular longitudinal wall strain</keyword>
  <keyword>strain rate pre and post medical therapy</keyword>
  <keyword>speckle tracking</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Ventricular Dysfunction, Left</mesh_term>
    <mesh_term>Ventricular Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sildenafil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
